Working together for better health. Partnering with Boehringer Ingelheim

Transcription

1 Working together for better health Partnering with Boehringer Ingelheim

2 Welcome to Boehringer Ingelheim Partnering Our vision Value through innovation is a reality A demonstrable history of innovation from our own research portfolio as well as from projects with our partners A new research strategy positions us for future success Significant investment in external collaborations will accelerate the next generation of medical breakthroughs A commitment to pursue, with our partners, the healthcare solutions of the future 2

3 Partnering: A Key Component of our Innovation Equation Partnering is an important part of our company strategy and forms an essential part of our drug discovery and development efforts More than 50% of our early-mid stage pipeline is anchored in collaborations with external partners External innovation at all stages of research and development is making an important and valued contribution to our organisation Our relationships range from discovery and development collaborations to commercial partnerships and full-scale, long-term alliances 3

4 Capabilities to Complement your Expertise Facilitating success for your project from science to sales Research Major research sites in the USA, Germany and Austria 5-yr investment commitment of 11B Clinical trials 988,860 patients, 1,414 studies, 115 substances, 95 countries 1 Market access Experienced market access team Integrated part of the R&D, marketing and regulatory teams Clinical development Dedicated phase 1 clinical unit Regulatory Three breakthrough therapy designations 10 approvals in 10 months 2 Sales & marketing Effectively translates R&D achievements into brand successes Approved by the US Food and Drug Administration and/or the European Medicines Agency; August 2014 May

5 Our Partnering Interests Our partnering focus encompasses opportunities across the entire drug discovery and development value chain: Building on our strengths by seeking partnerships in our established therapeutic areas Collaborating on new biology and new therapeutic concepts within our core areas Creating synergies by identifying and exploring unifying scientific platforms and enabling technologies with potential across our therapeutic areas Harnessing emerging science and technology beyond our therapeutic areas: Research Beyond Borders 5

6 Our Partnering Focus 6

7 In Focus: Oncology Actively pursuing new early-science collaborations in our areas of partnering interest: Cancer cell-directed therapies Growth signaling e.g. RTKs, Wnt, Notch, KRAS, MET, MYC Regulation of apoptosis Epigenetic regulation Regulation of protein homeostasis Immune cell-directed therapies Novel immune regulatory checkpoints Cancer vaccines and oncolytic viruses Novel tumor antigens including tumor-specific MHCpeptide presentation Research center of excellence for Oncology is located in Austria, with the Cancer Immunology research group located in the USA 7

8 Working Together in Oncology Large number of collaborations with academic partners and biotechnology companies help to advance our search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities Partnering with ViraTherapeutics to jointly develop a next-generation oncolytic virus therapy platform and lead candidate Vesicular Stomatitis Virus glycoprotein Major in-licensing deal of novel therapeutic lung cancer vaccine with CureVac Collaborating with the University of Texas MD Anderson Cancer Center to develop medicines for pancreatic ductal carcinoma Working together with the University of Toronto, University Health Network and Mount Sinai Hospital to explore different therapeutic concepts within the ubiquitin system Discovery Research Pre-clinical development Clinical development Regulatory approval/ Phase IV Visual does not necessarily reflect the stage of development for the partnership highlighted 8

9 Biopharmaceutical Production Expertise Industry-leading expertise in development and manufacturing of biopharmaceuticals More than 35 years experience in mammalian and microbial host systems Flexible scale cgmp production in multi-product facilities approved by the major authorities (FDA, EMA, MHLW) Provides the entire production technology chain from DNA to fill and finish at facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China) Total commercial capacity of more than 200,000 litres with flexible scales between 400 and 12,000 litres For products derived from microbial fermentation technology more than 12,000 litres of commercial capacity with flexible scales from 200 litres to 4,500 litres 9

10 Partnering Approach

11 Project-centric Transaction Strategies We seek to create an agreement that meets our mutual needs and facilitates success for your project based on the 4 Cs : Commitment Credibility Creativity Common sense We explore multiple ways to work together to progress novel science e.g.: Bi-lateral partnerships with academia and industry Public-private partnerships Venture-fund investment Global Strategic Alliance Research Collaboration Asset Purchase Alternative Transaction Structures License Agreement Option Agreement Public- Private Partnerships Boehringer Ingelheim Venture Fund 11

12 Making the Difference: People and Science A track record of partnering extending beyond 10 years Lasting partnerships that deliver real results for both parties Relationships based on mutual trust and shared goals Long tradition of scientific excellence A philosophy that embraces creativity and innovation Following our curiosity to pursue the healthcare solutions of the future 12

13 Working Together for Better Health A family-owned company with a distinctive and deep-rooted culture Company values which characterise the nature of Boehringer Ingelheim and which extend equally to our relationships with our partners A history of long-term, sustained performance and investment Commitment to long-term research focus extending equally to our alliances Capabilities, from science to sales, to complement your expertise and facilitate success for our project Respect Empathy Passion Trust 13

14 14

15 Worldwide Partnering Contacts Business Development and Licensing Dr. Paola Casarosa Corporate Vice President, Business Development and Licensing Ingelheim, Germany Phone: CardioMetabolic Diseases Respiratory Dr. Johannes Zanzinger Biberach, Germany Phone: Dr. Monica Cheng Ridgefield, CT, USA Phone: Dr. Silke Hobbie Biberach, Germany Phone: Dr. Peter Seither Biberach, Germany Phone: peter.seither@boehringeringelheim.com Central Nervous System Diseases Technologies Boston, USA Dr. Klaus Mendla Biberach, Germany Phone: klaus.mendla@boehringeringelheim.com Dr. Laura Corradini Biberach, Germany Phone: laura.corradini@boehringeringelheim.com Dr. Bernd Nosse Biberach, Germany Phone: bernd.nosse@boehringeringelheim.com Mr. Imran Nasrullah Boston, MA, USA Phone: imran.nasrullah@boehringeringelheim.com Immunology Interim Cancer Immunology and Immune Modulation Asia Dr. Ioannis Sapountzis Ingelheim, Germany Phone: ioannis.sapountzis@boehringeringelheim.com Dr. Scott DeWire Ridgefield, CT, USA Phone: scott.dewire@boehringeringelheim.com Dr. Takeshi Kono Tokyo, Japan Phone: takeshi.kono@boehringeringelheim.com Ms. Irene Liu Shanghai, China Phone: irene.liu@boehringeringelheim.com Oncology Dr. Ioannis Sapountzis Ingelheim, Germany Phone: ioannis.sapountzis@boehringeringelheim.com Dr. Emilio Erazo-Fischer Ingelheim, Germany Phone: emilio.erazofischer@boehringer-ingelheim.com

16 Working together for better health Partnering with Boehringer Ingelheim